96 related articles for article (PubMed ID: 16785077)
1. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy.
Bachrach SJ; Kecskemethy HH; Harcke HT; Lark RK; Miller F; Henderson RC
J Clin Densitom; 2006; 9(2):167-74. PubMed ID: 16785077
[TBL] [Abstract][Full Text] [Related]
2. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Plotkin H; Coughlin S; Kreikemeier R; Heldt K; Bruzoni M; Lerner G
Dev Med Child Neurol; 2006 Sep; 48(9):709-12. PubMed ID: 16904014
[TBL] [Abstract][Full Text] [Related]
3. Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy.
Bachrach SJ; Kecskemethy HH; Harcke HT; Hossain J
Dev Med Child Neurol; 2010 Sep; 52(9):837-42. PubMed ID: 20573180
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
Henderson RC; Lark RK; Kecskemethy HH; Miller F; Harcke HT; Bachrach SJ
J Pediatr; 2002 Nov; 141(5):644-51. PubMed ID: 12410192
[TBL] [Abstract][Full Text] [Related]
5. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
Howe W; Davis E; Valentine J
Dev Neurorehabil; 2010 Feb; 13(1):31-6. PubMed ID: 20067343
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy.
Henderson RC; Kairalla JA; Barrington JW; Abbas A; Stevenson RD
J Pediatr; 2005 Jun; 146(6):769-75. PubMed ID: 15973316
[TBL] [Abstract][Full Text] [Related]
9. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
10. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
11. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
12. Prevention of postoperative osteopenia using IV pamidronate: a pilot study.
Hobby BD; Dominguez-Bartmess S; Szalay EA
J Pediatr Orthop; 2013; 33(7):763-7. PubMed ID: 23872799
[TBL] [Abstract][Full Text] [Related]
13. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate Treatment to Prevent Reoccurring Fractures in Children With Cerebral Palsy.
Sees JP; Sitoula P; Dabney K; Holmes L; Rogers KJ; Kecskemethy HH; Bachrach S; Miller F
J Pediatr Orthop; 2016 Mar; 36(2):193-7. PubMed ID: 25757207
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M
J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
17. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate increases trabecular bone mineral density in immobilization osteopenia in male rats.
Huuskonen J; Arnala I; Olkkonen H; Alhava E
Ann Chir Gynaecol; 2001; 90(1):37-42. PubMed ID: 11336368
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
[TBL] [Abstract][Full Text] [Related]
20. Quantifying postoperative bone loss in children.
Szalay EA; Harriman D; Eastlund B; Mercer D
J Pediatr Orthop; 2008; 28(3):320-3. PubMed ID: 18362797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
